Tegretol Suspension

— THERAPEUTIC CATEGORIES —
  • Nonnarcotic analgesics
  • Seizure disorders

Tegretol Suspension Generic Name & Formulations

General Description

Carbamazepine 100mg/5mL; citrus-vanilla flavor; contains sorbitol.

Pharmacological Class

Dibenzazepine.

How Supplied

Tabs—60, 100; XR tabs—100; Susp—450mL

Mechanism of Action

Tegretol appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. It is chemically unrelated to other anticonvulsants or other drugs used to control the pain of trigeminal neuralgia. The mechanism of action remains unknown.

Tegretol Suspension Indications

Indications

Trigeminal or glossopharyngeal neuralgia.

Tegretol Suspension Dosage and Administration

Adult

Take with food. Give in 4 divided doses. Initially 50mg 4 times daily; increase if needed by up to 200mg/day. Max 1.2g/day. Maintenance: usually 400–800mg daily. Taper dosage or discontinue if possible at 3 month intervals.

Children

Not established.

Tegretol Suspension Contraindications

Contraindications

History of bone marrow depression. Sensitivity to tricyclic antidepressants. During or within 14 days of MAOIs. Concomitant nefazodone.

Tegretol Suspension Boxed Warnings

Boxed Warning

Serious dermatologic reactions and HLA-B*1502 allele. Aplastic anemia and agranulocytosis.

Tegretol Suspension Warnings/Precautions

Warnings/Precautions

Evaluate for presence of HLA-B*1502 allele (esp. in Asians), if present carbamazepine should not be used; increased risk of severe dermatologic reactions. Patients known to be HLA-A*3101 positive; increased risk of hypersensitivity reactions. Discontinue at the first sign of rash, or if anaphylaxis or angioedema occurs (do not rechallenge). Prior adverse hematologic reaction to any drug. Do baseline CBCs then periodically; discontinue if significant bone marrow depression occurs. History of cardiac conduction disturbance. 2nd or 3rd degree AV heart block. Cardiac, hepatic, or renal damage. Avoid in hepatic porphyria. Monitor ophthalmic, hepatic, and renal function. Increased intraocular pressure; monitor. Mixed seizure disorder with atypical absence seizures (may increase generalized convulsions). Monitor for new or worsening depression, suicidal thoughts, unusual changes in behavior. Activation of latent psychosis. Use minimum effective dose; adjust gradually. Avoid abrupt cessation. Convert tabs to susp with same quantity of mg/day in smaller, more frequent doses; convert tabs to XR on daily mg/mg basis. Suspension: avoid in fructose intolerance. Elderly. Labor & delivery. Pregnancy; can cause fetal harm. Nursing mothers; not recommended.

Tegretol Suspension Pharmacokinetics

Absorption

Suspension, tablets, and XR tablets deliver equivalent amounts of drug to the systemic circulation. The suspension was absorbed somewhat faster, and the XR tablet slightly slower, vs the conventional tablet. Peak plasma levels occurred at ~1.5 hours (suspension), 4–5 hours (tablets), and 3–12 hours (XR tablets).

Distribution

Plasma protein bound: 76%.

Metabolism

Hepatic (CYP3A4).

Elimination

Renal (72%), fecal (28%). Half-life: 25–65 hours.

Tegretol Suspension Interactions

Interactions

See Contraindications. Cross-sensitivity possible with oxcarbazepine. Avoid concomitant temsirolimus, lapatinib; if necessary, adjust dose. Concomitant rivaroxaban, apixaban, dabigatran, edoxaban; avoid. Potentiated by CYP3A4 inhibitors (eg, aprepitant, cimetidine, ciprofloxacin, danazol, diltiazem, macrolides, erythromycin, troleandomycin, clarithromycin, fluoxetine, fluvoxamine, trazodone, olanzapine, loratadine, terfenadine, omeprazole, oxybutynin, dantrolene, isoniazid, niacinamide, nicotinamide, ibuprofen, propoxyphene, azole antifungals, acetazolamide, verapamil, ticlopidine, grapefruit juice, protease inhibitors), loxapine, quetiapine, valproate. Antagonized by CYP3A4 inducers (eg, cisplatin, doxorubicin, felbamate, fosphenytoin, rifampin, phenobarbital, phenytoin, primidone, methsuximide, theophylline, aminophylline). May potentiate cyclophosphamide. May antagonize phenytoin, warfarin, doxycycline, theophylline, haloperidol, acetaminophen, alprazolam, clozapine, oral contraceptives, anticonvulsants, aripiprazole, others metabolized by CYP3A4. May increase lithium toxicity, isoniazid-induced hepatotoxicity. Monitor tacrolimus, valproate levels. Symptomatic hyponatremia possible with diuretics. Caution with alcohol. Monitor for rapid recovery from neuromuscular blockade. May alter thyroid function with other anticonvulsants. Do not give susp formulation simultaneously with other liquid drugs or diluents. May interfere with some pregnancy tests, thyroid function tests. See full labeling.

Tegretol Suspension Adverse Reactions

Adverse Reactions

Drowsiness, dizziness, unsteadiness, nausea, vomiting; hyponatremia, bone marrow depression, DRESS/multiorgan hypersensitivity, cardiac and hepatic effects, suicidal ideation; rare: serious skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), aplastic anemia, agranulocytosis, anaphylaxis.

Tegretol Suspension Clinical Trials

See Literature

Tegretol Suspension Note

Not Applicable

Tegretol Suspension Patient Counseling

See Literature

Tegretol Suspension Generic Name & Formulations

General Description

Carbamazepine 100mg/5mL; citrus-vanilla flavor; contains sorbitol.

Pharmacological Class

Dibenzazepine.

How Supplied

Tabs—60, 100; XR tabs—100; Susp—450mL

Mechanism of Action

Tegretol appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. It is chemically unrelated to other anticonvulsants or other drugs used to control the pain of trigeminal neuralgia. The mechanism of action remains unknown.

Tegretol Suspension Indications

Indications

Generalized tonic-clonic, partial or mixed seizures.

Tegretol Suspension Dosage and Administration

Adult

Take with food. Give in 3–4 divided doses. Initially 100mg 4 times daily; increase weekly if needed by up to 200mg/day. 12–15yrs: max 1g daily; >15yrs: usual max 1.2g daily (rarely, max 1.6g daily). Usual maintenance: 800mg–1.2g/day.

Children

Take with food. Give in 3–4 divided doses. <6yrs: initially 10–20mg/kg/day in 4 divided doses; increase weekly if needed. Maintenance: usual max <35mg/kg/day. 6–12yrs: initially 50mg 4 times daily; increase weekly if needed by up to 100mg/day; max 1g daily. Usual maintenance: 400mg–800mg/day.

Tegretol Suspension Contraindications

Contraindications

History of bone marrow depression. Sensitivity to tricyclic antidepressants. During or within 14 days of MAOIs. Concomitant nefazodone.

Tegretol Suspension Boxed Warnings

Boxed Warning

Serious dermatologic reactions and HLA-B*1502 allele. Aplastic anemia and agranulocytosis.

Tegretol Suspension Warnings/Precautions

Warnings/Precautions

Evaluate for presence of HLA-B*1502 allele (esp. in Asians), if present carbamazepine should not be used; increased risk of severe dermatologic reactions. Patients known to be HLA-A*3101 positive; increased risk of hypersensitivity reactions. Discontinue at the first sign of rash, or if anaphylaxis or angioedema occurs (do not rechallenge). Prior adverse hematologic reaction to any drug. Do baseline CBCs then periodically; discontinue if significant bone marrow depression occurs. History of cardiac conduction disturbance. 2nd or 3rd degree AV heart block. Cardiac, hepatic, or renal damage. Avoid in hepatic porphyria. Monitor ophthalmic, hepatic, and renal function. Increased intraocular pressure; monitor. Mixed seizure disorder with atypical absence seizures (may increase generalized convulsions). Monitor for new or worsening depression, suicidal thoughts, unusual changes in behavior. Activation of latent psychosis. Use minimum effective dose; adjust gradually. Avoid abrupt cessation. Convert tabs to susp with same quantity of mg/day in smaller, more frequent doses; convert tabs to XR on daily mg/mg basis. Suspension: avoid in fructose intolerance. Elderly. Labor & delivery. Pregnancy; can cause fetal harm. Nursing mothers; not recommended.

Tegretol Suspension Pharmacokinetics

Absorption

Suspension, tablets, and XR tablets deliver equivalent amounts of drug to the systemic circulation. The suspension was absorbed somewhat faster, and the XR tablet slightly slower, vs the conventional tablet. Peak plasma levels occurred at ~1.5 hours (suspension), 4–5 hours (tablets), and 3–12 hours (XR tablets).

Distribution

Plasma protein bound: 76%.

Metabolism

Hepatic (CYP3A4).

Elimination

Renal (72%), fecal (28%). Half-life: 25–65 hours.

Tegretol Suspension Interactions

Interactions

See Contraindications. Cross-sensitivity possible with oxcarbazepine. Avoid concomitant temsirolimus, lapatinib; if necessary, adjust dose. Concomitant rivaroxaban, apixaban, dabigatran, edoxaban; avoid. Potentiated by CYP3A4 inhibitors (eg, aprepitant, cimetidine, ciprofloxacin, danazol, diltiazem, macrolides, erythromycin, troleandomycin, clarithromycin, fluoxetine, fluvoxamine, trazodone, olanzapine, loratadine, terfenadine, omeprazole, oxybutynin, dantrolene, isoniazid, niacinamide, nicotinamide, ibuprofen, propoxyphene, azole antifungals, acetazolamide, verapamil, ticlopidine, grapefruit juice, protease inhibitors), loxapine, quetiapine, valproate. Antagonized by CYP3A4 inducers (eg, cisplatin, doxorubicin, felbamate, fosphenytoin, rifampin, phenobarbital, phenytoin, primidone, methsuximide, theophylline, aminophylline). May potentiate cyclophosphamide. May antagonize phenytoin, warfarin, doxycycline, theophylline, haloperidol, acetaminophen, alprazolam, clozapine, oral contraceptives, anticonvulsants, aripiprazole, others metabolized by CYP3A4. May increase lithium toxicity, isoniazid-induced hepatotoxicity. Monitor tacrolimus, valproate levels. Symptomatic hyponatremia possible with diuretics. Caution with alcohol. Monitor for rapid recovery from neuromuscular blockade. May alter thyroid function with other anticonvulsants. Do not give susp formulation simultaneously with other liquid drugs or diluents. May interfere with some pregnancy tests, thyroid function tests. See full labeling.

Tegretol Suspension Adverse Reactions

Adverse Reactions

Drowsiness, dizziness, unsteadiness, nausea, vomiting; hyponatremia, bone marrow depression, DRESS/multiorgan hypersensitivity, cardiac and hepatic effects, suicidal ideation; rare: serious skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), aplastic anemia, agranulocytosis, anaphylaxis.

Tegretol Suspension Clinical Trials

See Literature

Tegretol Suspension Note

Not Applicable

Tegretol Suspension Patient Counseling

See Literature

Images